Current possibilities in diagnosis and treatment of diffuse large B cell lymphoma in children and adolescents: results of Pediatric Hematology and Oncology Research Institute of N.N.Blokhin Russian Cancer Research Center, international experience


Cite item

Full Text

Abstract

Background/Objectives. At the present time results of some pediatric protocols (FAB/LMB96 with and without rituximab (±R), B-NHL-BFM90/95, B-NHL-2004m) were published but prognostic significance of markers, such as: non-GCB DLBCL subtype, C-MYC, pSTAT3, BCL2/C-MYC coexpression, C-MYC, BCL2/C-MYC gene rearrangements in childhood DLBCL is unknown. In this article there was presented results of treatment childhood DLBCL according to protocols IDM-NHL-BFM90, B-NHL-BFM95 ± rituximab in view of morpho-immunological tumor’s features.Design/Methods. From 1994 to 2015 fifty one pediatric patients with DLBCL were included in trials IDM-NHL-BFM90, B-NHL-BFM95 ± rituximab. Male/female ratio was 2/1. Median age - 9.9±0.5 years (range from 2 till 16). Stage III-IV were revealed in 29 patients (56.9%), R3-R4-risk group - in 26 (50.9%). GCB/non-GCB DLBCL subtypes were assessed by Hans, Tally and Visco-Young immunohistochemical algorithms. Cutoff values of 40% for MYC, 70% for BCL2, 50% for pSTAT3 were established. MYC gene rearrangement was assessed by FISH using locus-specific MYC (8q24) tricolor breakapart probe, MYC (8q24) SE8 control probe and locus-specific MYC, BCL2, BCL6 dual - color breakapart probes.Results. GCB/non-GCB DLBCL subtypes were revealed in 13 (54.2%) and 11 (45.8%) out of 24 cases; in 10 (41.7%)and 14 (58.3%) out of 24 cases according to Hans algorithm, 10 (43.5%) and 13 (56.5%) out of 23 cases according to Visco-Young algorithm; in 7 (63.6%) and 4 (36.4%) out of 11 cases according to Tally algorithm. There was a trend to determine the difference between GCB/non-GCB subgroups of DLBCL according immunohistochemical algorithms (p=0.058). Ten (62.5%) out of 16 DLBCL samples were positive for MYC, 9 (40.9%) out of 22 - for BCL2, 2 (18.2%) out of 11 - for BCL2/C-MYC coexpression, 1 (9.1%) out of 11 - for pSTAT3. MYC gene rearrangement was revealed in 3 (20%) out of 15 patients. There was determined a statistically significant relationship between MYC expression>70% and MYC gene rearrangement in patients with III - IV stages of disease and R3 - R4 risk group. BCL2 and BCL-6 gene rearrangements were not revealed. Five-year overall survival (OS), event-free survival (EFS) were 90.3±5.3%, a median follow-up was 63.3±7.9 months, relapse-free (RFS) was 100%, a median follow-up was 69.5±7.9 months. There is not revealed any influence of investigated markers on OS, EFS and RFS.Conclusion. Number of patients in this study is not enough to estimate authentic prognostic significance of these markers but high-intensive B-NHL-BFM95 ± rituximab chemotherapy showed good therapeutic effect in our patients. This study will be continued.

About the authors

A S Levashov

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: andreyslevashov@mail.ru
науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

A M Kovrigina

National Research Center for Hematology of the Ministry of Health of the Russian Federation

д-р биол. наук, проф., зав. патологоанатомическим отд-нием ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4

T T Valiev

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

E S Belyaeva

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, врач отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

A V Popa

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. отд-нием химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

G L Mentkevich

Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием химиотерапии гемобластозов и детским отд-нием трансплантации костного мозга НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

References

  1. Reiter A. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007; 1: 285-96.
  2. Burkhardt В, Oschlies I, Klapper W. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011; 25: 153-60.
  3. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: Медицинское информационное агентство, 2007; с. 212.
  4. Swerdlow S.H, Campo E, Harris N.L. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Fourth edition. 2008.
  5. Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Hematol 2008; 142: 329-47.
  6. Jaffe E.S, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology 2011; p. 506-14.
  7. Heerema N.A, Bernheim A.B, Lim M.S. Meeting report, State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: summary report of workshop at the first international symposium on childhood and adolescent non-Hodgkin lymphoma. Ped Blood Cancer 2005; 45: 616-22.
  8. Oschlies I, Klapper W, Zimmermann M. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal - center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Francfurt-Munster) multicenter trial. Blood 2006; 107 (10): 4047-52.
  9. Miles R, Raphael M, Mc Carthy K. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c - myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Ped Blood Cancer 2008; 51 (3): 369-74.
  10. Roschewski M, Staudt L.M, Wilson W.H. Diffuse large B-cell lymphoma - treatment approaches in the molecular era. Nat Rev Clin Oncol 2014; 11 (1): 12-23.
  11. Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol 2011; 28: 167-77.
  12. Барышников А.Ю., Валиев Т.Т., Губин А.Н. Лимфомы у детей: практическое руководство. Под ред. Г.Л.Менткевича, С.А.Маяковой. М.: Практическая медицина, 2014.
  13. Менткевич Г.Л., Маякова С.А. Лимфомы у детей. М.: Практическая медицина, 2014.
  14. Laver J.H, Kraveka J.M, Hutchison R.E. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 2005; 23 (3): 541-7.
  15. Tsurusawa M, Mori T, Kikuchi A. Improved treatment results of Children with B-cell non-Hodgkin lymphoma: a report from Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Ped Blood Cancer 2014; 61: 1215-21.
  16. Goldman S, Smith L, Anderson J.R. Rituximab and FAB/LMB96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology group report. Leukemia 2013; 27: 1174-7.
  17. Barth M.J, Goldman S, Smith L. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: a Children’s Oncology group report. Br J Haematol 2013; 162: 678-83.
  18. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Возможности и проблемы современной терапии неходжкинских лимфом у детей и подростков. Педиатрия. 2011; 90 (4): 37-43.
  19. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ2004м с применением ритуксимаба и модифицированного протокола Б-НХЛ БФМ 90. Онкогематология. 2009; 3: 4-14.
  20. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Лечение диффузной Б-крупноклеточной лимфомы у детей с применением интенсивной химиотерапии с ритуксимабом: предварительные результаты. Детская онкология. 2007; 3-4: 51-6.
  21. Klapper W, Kreuz M, Kohler C.W. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119 (8): 1882-7.
  22. Chen Y, Sun X.F, Cai R.Q. Germinal - center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. Chin J Cancer 2013; 32 (10): 561-6.
  23. Poirel H.A, Cairo M.S, Heerema N.A. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009; 23 (2): 323-31.
  24. Reiter A, Schrappe M, Tieman M. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group Trial NHL-BFM90. Blood 1999; 94 (10): 3294-306.
  25. Woessmann W, Seidemann K, Mann G, Zimmermann M. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 2005; 105: 948-58.
  26. Meyer P.N, Fu K, Greiner T.G. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200-7.
  27. Perry A.M, Zdravko M. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19 (3): 214-26.
  28. Culpin R.E, Sieniawski M, Angus B. Prognostic significance of immunohistochemistry - based markers and algorithms in immunochemotherapy - treated diffuse large B cell lymphoma patients. Histopathology 2013; 63: 788-801.
  29. Visco Y, Li Y, Xu-Monette Z.Y. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Prorram Study. Leukemia 2012; 26 (9): 2103-13.
  30. Cox C.M, Di Napoli A, Scarpino S. Clinicopathologic characterization of diffuse large B cell lymphoma with an associated serum monoclonal IgM component. PLOS one 2014. http://www.plosone.org/article/fetchObject.action?uri=info:doi/ 10.1371/journal.pone.0093903&representation=PDF
  31. Hu S, Xu-Monette Z.Y, Balasubramanyam A. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-24.
  32. Hu S, Xu-Monette Z.Y, Tzankov A. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high - risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121 (20): 4021-31.
  33. Ichikava S, Fukuhara N, Katsushima H. Association between BACH2 expression and clinical prognosis in diffuse large B cell lymphoma. Cancer Sci 2014; 105 (4): 437-44.
  34. Laurent C, Do C, Gascoyne R.D. Anaplastic lymphoma kinase - positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27 (25): 4211-6.
  35. Miyazaki K, Yamaguchi M, Suzuki R. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
  36. Nam S.J, Go H, Paik J.H. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia Lymphoma 2014; 55 (11): 2466-76.
  37. Ok C.J, Xu-Monette Z.Y, Tzankov A. STAT3 expression and clinical inplications in de novo diffuse large B cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program. Blood 2013; 122 (21). https://ash.confex.com/ash/2013/webprogram/Paper60938.html.
  38. Ok C.Y, Chen J, Xu-Monette Z. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clinical Cancer Res 2014; 20 (19): 5113-23.
  39. Tzankov A, Xu-Monette Z, Gerhard M. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathol 2014; 27: 958-71.
  40. Valera A, Colomo L, Martinez A. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathol 2013; 26: 1329-37.
  41. Visco C, Tzankov A, Xu-Monette Z. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica 2013; 98 (2): 255-63.
  42. Wu Z.L, Song Y.Q, Shi Y.F. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011; 4 (31). http://www.jhoonline.org/content/pdf/1756-8722-4-31.pdf
  43. Xie M, Wei Y, Ley Y. The prognostic significance of tumor - associated macrophages and NK cells in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2014; 124 (21). http://www.bloodjournal.org/content/124/21/5390.full.pdf
  44. Yamamoto W, Nakamura N, Tomita N. Human leukocyte antigen - DR expression on flow cytometry and tumor associated macrophages in diffuse large B cell lymphoma treated by: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cogort study. Leukemia/Lymphoma 2014; 55 (12): 2721-7.
  45. Imbach P, Kuhne Th, Arceci R. Pediatric Oncology. A comprehensive guide. 2006; p. 61-9.
  46. Rosolen A, Perkins S.L, Pinkerton C.R. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015; 33 (18): 2106-11.
  47. Apostolopoulos D.J, Papandrianos N.I, Symeonidis A. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nuclear Med 2010; 24: 639-47.
  48. Bardi E, Csoka M, Garai I. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathol Oncol Res 2014; 20: 139-43.
  49. Dabaja B, Phan J, Mawlawi O. Clinical implications of PET-negative residual CT masses after chemotherapy for diffuse large B-cell lymphoma. Leukemia Lymphoma 2013; 54 (12): 2631-8.
  50. Furth C, Steffen I.G, Erdrich A.S. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI res 2013; 3 (71). http://www.ejnmmires.com /content/3/1/71
  51. Lange J, Burghardt B. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malign Rep 2013; 8 (3): 226-35.
  52. Scott R, Jo-Anne V, Aliakbar S. Characteristic expression patterns of TCL1, CD38, CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 2008; 32 (1): 113-22.
  53. Green T.M, Nielsen O, de Stricker K. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012; 36 (4): 612-9.
  54. Kondratieva S, Duraisamy S, Unitt C.L. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol 2011; 35 (10): 1531-9.
  55. Togunaga T, Tomita A, Sugimoto K. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry - positive and flow cytometry - negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci 2014; 105 (1): 35-43.
  56. Song G, Cho W.C, Gu L. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Med Oncol 2014; 31 (56). http://link.springer.com.sci-hub.org/article/10.1007/s12032-014-0056-y
  57. Fen Liu, Ding H, Jin X. FCGR3A 158 V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014; 33: 616-23.
  58. Morschhauser F.A, Cartron G, Thieblemont C. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle - cell lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-9.
  59. Coiffier B, Radford J, Bosly A. A multicentre, phase II trial ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Hematol 2013; 163: 334-42.
  60. Viardot A, Goebeler M, Hess G. Treatment of relapsed/refractory diffuse large B cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open - label, phase II study. ASH annual meeting abstracts book. 2014; 4460. https://ash.confex.com/ ash/2014/webprogram/Paper 68589. Html
  61. Portell C.A, Wenzell C.M, Advani A.S. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl 2013; 5: 5-11.
  62. Schlegel P, Lang P, Zugmaier G. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99 (7): 1212-8.
  63. Stackelberg A, Locatelli F, Zugmaier G. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH annual meeting abstracts book. 2014; 2292. https://ash.confex. com/ash/ 2014/webprogram/Paper69576.html
  64. Schuster F.R, Stanglmaier M, Woessmann W. Immunotherapy with trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in pediatric high - risk patients with recurrent CD20-positive B-cell malignancies. Br J Haematol 2015; 169 (1): 90-102.
  65. Kochenderfer J.N, Dudley M.E, Kassim S.H. Chemotherapy - refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014. http://jco.ascopubs.org/content/early/2014/08/25/JCO. 2014.56.2025. full.pdf
  66. Wang Y, Zhang W.Y, Han Q.W. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor - modified T cells. Clin Immunol 2014; 155: 160-75.
  67. Maude S.L, Teachey D.T, Porter D.A. Chimeric antigen receptor (CAR) modified N cells induce durable remissions in children with relapsed/refractory ALL. Blood 2015; 125 (26): 4017-23.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies